Di Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Di Wang has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Ansheng Xie
The First School of Clinical Medicine, Southern Medical University; Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China
1 shared publication- Bo Chang
Department of Immunology School of Basic Medical Sciences Southern Medical University Guangzhou Guangdong China fimmu.com
1 shared publication Chengyi Li
The First School of Clinical Medicine, Southern Medical University; Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China
1 shared publication- Fan Deng
Department of Immunology School of Basic Medical Sciences Southern Medical University Guangzhou Guangdong China fimmu.com
1 shared publication - Jia Zhou
Department of Immunology, Guangdong Province Key Laboratory of Proteomics, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
1 shared publication - Jialiang Luo
Institute of Medical Research, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 16 July 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (7) , e015617
Blautia coccoides -derived acetate potentiates anti-PD-1 immunotherapy in melanoma by activating cytotoxic CD8 + T cells
Background: Gut microbiota can modulate cancer immunotherapy and enhance the efficacy of programmed cell death protein 1 (PD-1) blockade in tumors, yet the responsible microbes and underlying mechanisms remain incompletely understood. Methods: Publicly available anti-PD-1-treated melanoma microbiome cohorts were reanalyzed. Causal validation was performed using oral Blautia coccoides ( B. coccoides ) supplementation in B16-F10 melanoma-bearing mice. Untargeted and targeted liquid chromatography-tandem mass spectrometry-based metabolomics, CD8 + T-cell depletion, receptor identification and binding analyses, and downstream transcriptomic and biochemical assays were used to identify the key metabolite and investigate its mechanism of action. Results: We identified Blautia as enriched in melanoma patients responding to immune checkpoint inhibitors, with higher abundance associated with non-progression. In melanoma-bearing mice, oral B. coccoides suppressed tumor growth and increased intratumoral effector CD8 + T cells. Metabolomic profiling identified acetate as a prominent B. coccoides -associated metabolite. Acetate enhanced CD8 + T-cell effector function. CD8 + T-cell depletion largely abrogated the antitumor effects of both B. coccoides and acetate, supporting a central role for CD8 + T cells. Mechanistically, these findings support a model in which acetate is associated with a TLR3-linked signaling pathway in CD8 + T cells, accompanied by PI3K/Akt activation and enhanced effector function. Notably, B. coccoides or acetate potentiated anti-PD-1 therapy in mouse melanoma models, supporting their potential as adjunctive strategies for melanoma immunotherapy. Conclusions: These findings support a model of an acetate-TLR3-linked PI3K/Akt signaling axis linking microbiota-associated metabolites to CD8 + T cell-mediated antitumor immunity. Importantly, our study highlights both B. coccoides and its derivative, acetate, as preclinical adjunctive candidates to potentiate anti-PD-1 efficacy in melanoma.
- 16 July 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (7) , e015617
Open AccessBlautia coccoides -derived acetate potentiates anti-PD-1 immunotherapy in melanoma by activating cytotoxic CD8 + T cells
Background: Gut microbiota can modulate cancer immunotherapy and enhance the efficacy of programmed cell death protein 1 (PD-1) blockade in tumors, yet the responsible microbes and underlying mechanisms remain incompletely understood. Methods: Publicly available anti-PD-1-treated melanoma microbiome cohorts were reanalyzed. Causal validation was performed using oral Blautia coccoides ( B. coccoides ) supplementation in B16-F10 melanoma-bearing mice. Untargeted and targeted liquid chromatography-tandem mass spectrometry-based metabolomics, CD8 + T-cell depletion, receptor identification and binding analyses, and downstream transcriptomic and biochemical assays were used to identify the key metabolite and investigate its mechanism of action. Results: We identified Blautia as enriched in melanoma patients responding to immune checkpoint inhibitors, with higher abundance associated with non-progression. In melanoma-bearing mice, oral B. coccoides suppressed tumor growth and increased intratumoral effector CD8 + T cells. Metabolomic profiling identified acetate as a prominent B. coccoides -associated metabolite. Acetate enhanced CD8 + T-cell effector function. CD8 + T-cell depletion largely abrogated the antitumor effects of both B. coccoides and acetate, supporting a central role for CD8 + T cells. Mechanistically, these findings support a model in which acetate is associated with a TLR3-linked signaling pathway in CD8 + T cells, accompanied by PI3K/Akt activation and enhanced effector function. Notably, B. coccoides or acetate potentiated anti-PD-1 therapy in mouse melanoma models, supporting their potential as adjunctive strategies for melanoma immunotherapy. Conclusions: These findings support a model of an acetate-TLR3-linked PI3K/Akt signaling axis linking microbiota-associated metabolites to CD8 + T cell-mediated antitumor immunity. Importantly, our study highlights both B. coccoides and its derivative, acetate, as preclinical adjunctive candidates to potentiate anti-PD-1 efficacy in melanoma.
- Open Access
- 15 April 2023
- Published by Wiley in Mediators of Inflammation
- Vol. 2023, 1-8
The Role of TSLP in Atopic Dermatitis: From Pathogenetic Molecule to Therapeutical Target
Atopic dermatitis (AD) is a kind of chronic skin disease with inflammatory infiltration, characterized by skin barrier dysfunction, immune response dysregulation, and skin dysbiosis. Thymic stromal lymphopoietin (TSLP) acts as a regulator of immune response, positively associated with AD deterioration. Mainly secreted by keratinocytes, TSLP interacts with multiple immune cells (including dendritic cells, T cells, and mast cells), following induction of Th2-oriented immune response during the pathogenesis of AD. This article primarily focuses on the TSLP biological function, the relationship between TSLP and different cell populations, and the AD treatments targeting TSLP.
- 15 April 2023
- Published by Wiley in Mediators of Inflammation
- Vol. 2023, 1-8
Open AccessThe Role of TSLP in Atopic Dermatitis: From Pathogenetic Molecule to Therapeutical Target
Atopic dermatitis (AD) is a kind of chronic skin disease with inflammatory infiltration, characterized by skin barrier dysfunction, immune response dysregulation, and skin dysbiosis. Thymic stromal lymphopoietin (TSLP) acts as a regulator of immune response, positively associated with AD deterioration. Mainly secreted by keratinocytes, TSLP interacts with multiple immune cells (including dendritic cells, T cells, and mast cells), following induction of Th2-oriented immune response during the pathogenesis of AD. This article primarily focuses on the TSLP biological function, the relationship between TSLP and different cell populations, and the AD treatments targeting TSLP.